← 返回

乳腺癌免疫治疗的最新进展:综述

英文原题:Recent Advances in Immunotherapy for Breast Cancer: A Review.

查看英文原题

Recent Advances in Immunotherapy for Breast Cancer: A Review.

PubMed 2024/08/27(内容时间) Breast Cancer (Dove Med Press) Q2 · IF 3.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

乳腺癌是全球女性最常见的恶性肿瘤之一,其发病率逐年上升,严重威胁女性的身心健康。三阴性乳腺癌(TNBC)是乳腺癌的一种特殊分子分型,即雌激素受体、孕激素受体和人表皮生长因子受体-2均为阴性。与其他分子分型的乳腺癌相比,三阴性乳腺癌(TNBC)侵袭转移能力强、复发率高、缺乏有效治疗靶点,临床治疗效果通常较差。化疗是过去采用的主要治疗手段。随着免疫时代的到来,免疫治疗在三阴性乳腺癌(TNBC)治疗中取得了许多进展,为三阴性乳腺癌的治疗带来了新的治疗希望。本文结合前沿医学研究结果,主要综述免疫治疗的研究进展,并总结三阴性乳腺癌(TNBC)免疫治疗的主要治疗方法,包括免疫检查点抑制剂、肿瘤疫苗、过继性免疫治疗以及中西医结合的应用。为三阴性乳腺癌(TNBC)的治疗提供了新思路。

展开英文摘要原文

Breast cancer is one of the most common malignant tumors in women in the world, and its incidence is increasing year by year, which seriously threatens the physical and mental health of women. Triple negative breast cancer (TNBC) is a special molecular type of breast cancer in which estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 are negative. Compared with other molecular types of breast cancer, triple-negative breast cancer (TNBC) has high aggressiveness and metastasis, high recurrence rate, lack of effective therapeutic targets, and usually poor clinical treatment effect. Chemotherapy was the main therapeutic means used in the past.

With the advent of the immune era, immunotherapy has made a lot of progress in the treatment of triple-negative breast cancer (TNBC), bringing new therapeutic hope for the treatment of triple-negative breast cancer.

This review combines the results of cutting-edge medical research, mainly summarizes the research progress of immunotherapy, and summarizes the main treatment methods of triple-negative breast cancer (TNBC) immunotherapy, including immune checkpoint inhibitors, tumor vaccines, adoptive immunotherapy and the application of traditional Chinese and western medicine. It provides a new idea for the treatment of triple negative breast cancer (TNBC).

论文信息

作者
Wen QE、Li L、Feng RQ、Li DH、Qiao C、Xu XS、Zhang YJ
第一作者单位
Graduate School, Hebei University of Chinese Medicine, Shijiazhuang, Hebei Province, People's Republic of China.China
通讯作者单位
Oncology Department II, The First Affiliated Hospital of Hebei University of Chinese Medicine (Hebei Province Hospital of Chinese Medicine), Key Laboratory of Integrated Chinese and Western Medicine for Gastroenterology Research, Shijiazhuang, Hebei Province, People's Republic of China.China
文献类型
综述
期刊
Breast cancer (Dove Medical Press)2024
原文标识
PubMed 39220564 · DOI 10.2147/BCTT.S482504